Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study.

"Conflict of Interest Disclosures Esra Karslioglu‐French reports personal fees from Horizon Therapeutics, outside the submitted work. Dan P. Zandberg reports institutional research support from Merck, Bristol Myers Squibb, AstraZeneca, Aduro, Macrogenics, GlaxoSmithKline, Lilly, and Astellas, outside the submitted work; and personal fees from Blueprint Medicines, outside the submitted work. Robert L. Ferris reports research funding from Astra‐Zeneca/MedImmune, Bristol Myers Squibb, Merck, Novasenta Consulting, and Tesaro, outside the submitted work; personal fees from Aduro Biotech, Bristol Myers Squibb, EMD Serano, MacroGenics Inc, Merck, Novasenta Consulting, personal fees from Numab Therapeutics AG, personal fees Pfizer, Sanofi, and Zymeworks Inc, outside the submitted work; and owns stock in Novasenta Consulting. Marina N. Nikiforova reports personal fees from Sonic Healthcare USA, outside the submitted work, and has a patent and copyrights with royalties paid related to ThyroSeq from the University of Pittsburgh. Yuri E. Nikiforov reports personal fees from Sonic Healthcare USA, outside the submitted work, and has a patent and copyrights with royalties paid related to ThyroSeq from the University of Pittsburgh. The remaining authors made no disclosures."

"Center for Scientific Review 10.13039/100005440"